TORONTO, ON – August 18, 2026 – PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) (the “Company” or “PharmaTher”), a life sciences company focused on personalized medicines, today announced that PERSONALIZ3D™, the Company’s integrated telehealth and pharmaceutical 3D printing platform for personalized medicines and peptides, is advancing toward commercialization through a collaboration agreement and the selection of Prescription Dispensing Laboratories, Inc. (PD Labs), a Section 503A compounding pharmacy, as its PERSONALIZ3D™ Center of Excellence.
 
This completes the first step of PharmaTher’s three-stage execution plan, announced on August 11, 2026: (i) establish the Center of Excellence; (ii) launch a controlled telehealth-enabled commercial program in the U.S.; and (iii) scale through placements of pharmaceutical 3D-printing systems with qualified pharmacy partners.
 
THE FIRST OPERATING HUB IN A LARGER PERSONALIZED MEDICINE AND PEPTIDE PLATFORM
 
Based in Cedar Park, Texas, PD Labs brings more than 26 years of compounding experience serving patients and prescribing practitioners across the United States, including experience with customized medications and peptides. As the PERSONALIZ3D™ Center of Excellence, PD Labs is intended to serve as both an initial commercial operating hub and a development site for a repeatable pharmacy deployment model.
 
Under the collaboration, PD Labs is expected to provide the real-world pharmacy environment and compounding expertise needed to evaluate the performance and integration of pharmaceutical 3D printing into pharmacy operations. Planned activities include: (i) supporting pharmacy fulfillment; (ii) establishing standardized workflows, quality controls and end-to-end traceability; and (iii) advancing patient-specific formulation development for medications and peptides, including individualized doses, combination formulations and release profiles. The Center is also expected to provide a working environment for system demonstrations and partner training.
 
Insights gained through these activities are expected to inform a scalable blueprint for future pharmacy onboarding, system deployment and ongoing support across PharmaTher’s PERSONALIZ3D™ network.

“When we introduced PERSONALIZ3D™, we set a three-stage plan with the Center of Excellence as the first step,” said Fabio Chianelli, Chief Executive Officer of PharmaTher. “PD Labs is the first step of that plan, bringing together pharmacy fulfillment and the manufacturing of 3D printed personalized medicines, including peptides, in a real-world setting. With PD Labs’ national reach, over 26 years of compounding medications and peptides experience, PharmaTher is now moving into early commercialization activities across the U.S. Together, we are actively building and validating how pharmaceutical 3D printing can be integrated into pharmacy workflows to deliver more precise, patient-specific medicines and peptides—including dose, formulation, release profile and dosage form—within compliant pharmacy practice.”

Ray Solano, RPh, MBA, CCN, President of PD Labs, commented: “Compounding has always been about precision and personalization. As the pharmacy Center of Excellence for PharmaTher’s PERSONALIZ3D™ platform, PD Labs will focus on pharmacy fulfillment, formulation development for medications, including peptides, and the integration of pharmaceutical 3D printing into real-world compounding workflows. We believe this work may enhance consistency, expand formulation capabilities and ultimately improve how we serve patients and prescribing practitioners.”

SIGNIFICANCE OF THIS MILESTONE FOR THE PERSONALIZ3D™ PLATFORM

Typical telehealth platforms may personalize access to care while continuing to dispense standardized or conventionally compounded medicines.

PERSONALIZ3D™ is being designed to personalize the prescribed medicine itself and connect that capability to a digital patient-access channel. PharmaTher believes the combination can create a reinforcing commercial model:

• Telehealth can create a digital front door for eligible patients, independent licensed healthcare providers and recurring engagement.
• The Center of Excellence can translate patient-specific prescriptions into documented workflows for formulation and fulfillment.
• Validated printing recipes, formulation know-how, operating procedures and implementation experience can strengthen the platform’s scalability and differentiation.
• Additional pharmacy-system placements can expand fulfillment capacity and geographic reach while supporting potential recurring revenue from consumables, software, service, training and validation.

This partnership-driven approach is designed to be capital-efficient and is intended to allow PharmaTher to focus resources on platform development, pharmaceutical 3D-printing systems, formulations, software, implementation tools, and commercialization, while PD Labs retains responsibility for its professional, regulatory, pharmacy, and patient-care obligations.

Initial work will build on PharmaTher’s collaboration with Craft Health and its CraftMake™ pharmaceutical 3D-printing platform, while also evaluating additional systems to define the technical and commercial requirements of the broader PERSONALIZ3D™ network.

BUILDING TOWARD A REPEATABLE COMMERCIAL MODEL

PharmaTher intends to use the Center of Excellence as the foundation for providing personalized medicine, including peptides, and for a broader distributed network of pharmacy-based pharmaceutical 3D-printing systems.

Personalized medicine also represents a significant broader market opportunity. Grand View Research estimates that the global personalized-medicine market could grow from approximately US$570 billion in 2024 to approximately US$1.2 trillion by 2033. PharmaTher believes pharmacy-based digital manufacturing could help it participate in this growth across peptides, longevity, metabolic health, pain management and other therapeutic categories in which patient-specific doses, combinations, release profiles or dosage forms may address patient needs.

According to the American Pharmacists Association, approximately 7,500 U.S. pharmacies engage in compounding. PharmaTher views this pharmacy base as a potentially significant long-term market for the PERSONALIZ3D™ network, including national prescription coverage, system placements, and recurring services.

The planned PERSONALIZ3D™ business model is intended to support multiple potential revenue channels, including:

• Telehealth platform participation and related technology or support services;
• 3D-printing system sales or other placement arrangements;
• Recurring consumables, software access, maintenance, technical support and training;
• Formulation, printing recipe and product development services; and
• Product sales, licensing and strategic or commercial partnerships.

“PERSONALIZ3D™ represents a shift from one-size-fits-all medicine to precision, on-demand therapeutics. We believe this is the beginning of a new category in healthcare.” — Fabio Chianelli

Learn more about PERSONALIZ3D™ and follow PharmaTher’s progress as the Company advances the platform toward commercialization at www.pharmather.com and www.personaliz3d.com.

ABOUT PD LABS

Founded by Ray Solano, RPh, MBA, CCN, a clinical pharmacist for 35 years and certified clinical nutritionist, Prescription Dispensing Laboratories, Inc. (PD Labs) is a Cedar Park, Texas-based specialty compounding pharmacy focused on customized medications and collaboration with prescribing practitioners. PD Labs has more than 26 years of compounding experience and a team that includes pharmacists, doctors of pharmacy and certified compounding technicians.

For more information, visit PDLabsRx.com.

ABOUT PERSONALIZ3D™

PERSONALIZ3D™ is PharmaTher’s personalized medicine and peptide platform designed to integrate telehealth, pharmaceutical 3D printing and qualified pharmacy fulfillment. The platform focuses on enabling patient-specific therapies, initially including peptides and other therapeutic categories where individualized doses, combinations, release profiles or dosage forms may address patient needs.
It is structured around two synergistic components: a telehealth-enabled pathway that supports prescription generation by independent licensed healthcare providers, and a pharmacy-based 3D-printing deployment model intended to enable scalable, on-demand production and fulfillment of personalized medicines.

For more information, visit PERSONALIZ3D.com.

ABOUT PHARMATHER

PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) is a life sciences company focused on personalized medicines.
For more information, visit PharmaTher.com.

FOR MORE INFORMATION

Fabio Chianelli
Chairman and Chief Executive Officer
PharmaTher Holdings Ltd.
Tel: 1-888-846-3171
Email: info@pharmather.com
Website: PharmaTher.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION

​This news release contains “forward-looking information” within the meaning of applicable Canadian securities laws. Forward-looking information is generally identifiable by words such as “anticipate,” “believe,” “expect,” “intend,” “plan,” “potential,” “propose,” “may,” “will,” “could,” “should,” “would” and similar expressions, or statements that certain events or conditions “will,” “may” or “could” occur. Forward-looking information reflects management’s current expectations, estimates, assumptions and beliefs as of the date of this news release and is subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied.

Forward-looking information in this news release includes, but is not limited to, statements concerning: the implementation, continuation and anticipated benefits of PharmaTher’s collaboration with PD Labs; the establishment, development and operation of the PERSONALIZ3D™ Center of Excellence; the anticipated roles and activities of PharmaTher and PD Labs; the use of PD Labs as an initial operating hub and development site; the future fulfillment of prescriptions generated through PERSONALIZ3D™ telehealth programs; and the establishment of standardized pharmacy workflows, printing recipes, quality controls, traceability systems, demonstrations and partner-training programs. Forward-looking information also includes statements regarding: the integration, evaluation, performance, validation and potential deployment of pharmaceutical 3D-printing systems, including CraftMake™ and other technologies; the development of patient-specific formulations, doses, combination formulations, release profiles and dosage forms for medications and peptides; the development and launch of a controlled U.S. telehealth-enabled commercial program; the execution of PharmaTher’s three-stage commercialization plan; future pharmacy onboarding and system placements; the creation of a distributed pharmacy fulfillment and 3D-printing network; and the potential expansion of fulfillment capacity and geographic coverage across the United States. Additional forward-looking information includes statements concerning: the ability of PERSONALIZ3D™ to provide more precise or patient-specific medicines; the scalability, differentiation and capital efficiency of the platform; the development of formulation know-how, intellectual property, software, data, operating procedures and implementation tools; the size and future growth of the personalized-medicine market; PharmaTher’s ability to participate in opportunities involving peptides, longevity, metabolic health, pain management and other therapeutic categories; and the potential generation of revenue from telehealth services, 3D-printing system sales or placements, consumables, software, maintenance, technical support, training, validation, formulation and product-development services, product sales, licensing and strategic or commercial partnerships. There can be no assurance that the contemplated early commercialization activities will result in commercial products, customers or revenue. The material assumptions underlying the forward-looking information include, among others, that: the collaboration between PharmaTher and PD Labs will be implemented and maintained as contemplated; the parties will have the personnel, expertise, infrastructure and financial resources required to perform their respective obligations; PD Labs will maintain the licences and regulatory standing required for its contemplated activities; pharmaceutical 3D-printing systems, materials, software and related workflows will perform as expected and can be successfully integrated into pharmacy operations; suitable formulations and printing recipes can be developed, reproduced and validated; required technology, equipment, supplies and services will remain available on commercially reasonable terms; PharmaTher will obtain sufficient financing to advance the PERSONALIZ3D™ platform; applicable laws and regulatory interpretations will not change in a materially adverse manner; qualified pharmacies, healthcare providers, technology partners and patients will adopt the platform; and third-party market and industry data are accurate and reasonably predictive of future conditions.

Actual results could differ materially because of numerous risks and uncertainties, including the risk that: the collaboration with PD Labs may be modified, delayed, suspended or terminated; the Center of Excellence may not become operational as contemplated or within the expected timeframe; the telehealth platform, pharmaceutical 3D-printing systems, formulations, printing recipes or related workflows may not be successfully developed, integrated, validated, scaled or commercialized; the systems may not achieve required standards for reproducibility, consistency, throughput, quality or traceability; PharmaTher may be unable to obtain sufficient financing or may experience development delays or higher-than-anticipated costs; commercial partners, prescribing practitioners, pharmacies or patients may not adopt the PERSONALIZ3D™ platform; and the contemplated activities may not generate revenue or achieve profitability. Additional risks include uncertainties relating to federal and state laws and regulatory requirements governing telehealth, pharmacy compounding, patient-specific prescriptions, bulk drug substances, peptides, pharmaceutical manufacturing, medical devices, software, professional practice, pharmacy licensure, corporate practice of medicine, fee arrangements, advertising, data privacy and healthcare services; changes in regulatory interpretations, enforcement policies or the availability of substances for compounding; the ability of PD Labs or future pharmacy partners to dispense prescriptions across applicable jurisdictions; dependence on PD Labs, Craft Health and other third-party partners and suppliers; competition; intellectual property protection; product liability; cybersecurity and data protection; supply-chain constraints; market acceptance; and general economic, capital-market and industry conditions. Market and industry data referenced in this release are based on third-party sources believed to be reliable but have not been independently verified by the Company. Market estimates are inherently uncertain and may differ materially from actual results. The estimated number of U.S. pharmacies engaged in compounding does not represent the number of pharmacies that are qualified, willing or expected to participate in the PERSONALIZ3D™ network and should not be interpreted as a forecast of customers, system placements or revenue.

Readers are cautioned not to place undue reliance on forward-looking information. All forward-looking information in this news release is expressly qualified by this cautionary note and speaks only as of the date of this release. Except as required by applicable securities laws, PharmaTher undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. Additional risks and uncertainties are described in the Company’s continuous disclosure filings available on SEDAR+. This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities.

FROM INITIAL COMMERCIAL FOOTPRINT TO A SCALABLE DISTRIBUTED NETWORK

PharmaTher plans to advance PERSONALIZ3D™ through three stages:

1. Establish the Center of Excellence

Select a qualified Section 503A pharmacy to serve as the PERSONALIZ3D™ Center of Excellence. Subject to final arrangements, the location is expected to serve as the initial pharmacy fulfillment center for telehealth prescriptions and to support the evaluation of pharmaceutical 3D-printing systems, product development, pharmacy workflows, demonstrations and partner training.

2. Launch the PERSONALIZ3D™ telehealth platform

Introduce a controlled telehealth-enabled commercial program connecting eligible patients with independent licensed healthcare providers and qualified pharmacy fulfillment.

3. Scale through pharmacy-system placements

PharmaTher plans to evaluate and introduce a controlled commercial rollout of pharmaceutical 3D-printing system placements with qualified U.S. Section 503A pharmacy partners and compound pharmacies in Canada.

According to the American Pharmacists Association, there are about 56,000 community-based or retail pharmacies in the United States. Of these, about 7,500 are compounding pharmacies. PharmaTher views this large pharmacy base as a potentially significant market for pharmaceutical 3D-printing systems and recurring services.

PERSONALIZ3D™ will build upon PharmaTher’s existing collaboration with Craft Health and its CraftMake™ pharmaceutical 3D-printing system, and may evaluate additional systems to support the Company’s goal of enabling personalized medicine through pharmaceutical 3D printing.

BUILDING LONG-TERM RECURRING REVENUE CHANNELS

The PERSONALIZ3D™ business model is designed to generate potential revenue from several parts of the ecosystem:

• Telehealth platform;
• 3D-printing system placements, consumables, software access, and ongoing maintenance and support; and
• Product development, sales, and licensing through strategic and commercial partnerships.

The telehealth and pharmacy network business units are designed to reinforce one another. The telehealth platform may help generate patient demand and prescriptions, while the pharmacy network may expand access and fulfillment capacity for personalized medicines. As both demand and system adoption grow, PharmaTher believes the platform could support broader and more scalable revenue opportunities.

ABOUT PERSONALIZ3D™

PERSONALIZ3D™ is PharmaTher’s planned personalized medicine platform designed to integrate telehealth, pharmaceutical 3D printing and qualified pharmacy fulfillment. The platform focuses on enabling patient-specific therapies, initially including peptides and other therapeutic categories where individualized doses, release profiles or dosage forms may address patient needs. It is structured around two synergistic components: a telehealth-enabled pathway that supports prescription generation by independent licensed healthcare providers, and a pharmacy-based 3D-printing deployment model that enables scalable, on-demand production and fulfillment of personalized medicines.

PERSONALIZ3D™ remains under development and has not commenced commercial operations.

For more information, visit personaliz3d.com.

ABOUT PHARMATHER
PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) is a life sciences company focused on personalized medicines. For more information, visit PharmaTher.com.

FOR MORE INFORMATION
Fabio Chianelli
Chairman and Chief Executive Officer
PharmaTher Holdings Ltd.
Tel: 1-888-846-3171
Email: info@pharmather.com
Website: PharmaTher.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION

This news release contains forward-looking information within the meaning of applicable securities laws. Forward-looking information includes statements regarding the development, launch and commercialization of PERSONALIZ3D™; the expansion of the Company’s strategy beyond peptides; the development and launch of a telehealth platform; the selection and operation of a Section 503A pharmacy Center of Excellence; the installation, evaluation and potential deployment of CraftMake™ pharmaceutical 3D-printing systems; the development of personalized formulations, digital printing workflows and pharmacy operating models; the potential sale, lease, subscription or other placement of pharmaceutical 3D-printing systems; the development of a pharmacy-based distribution network; the potential for a broader commercial relationship with Craft Health; the anticipated scalability of the PERSONALIZ3D™ ecosystem; and the potential generation of revenue from platform services, system placements, consumables, software, maintenance, training, support, intellectual property, products and strategic partnerships.

Forward-looking information is based on management’s current expectations, estimates, assumptions and beliefs and is subject to a number of known and unknown risks and uncertainties that could cause actual results to differ materially. These risks include, among others, the risk that PERSONALIZ3D™ or any of its components may not be successfully developed, launched or commercialized; that the telehealth platform may not be implemented as planned or may not generate expected demand; that the Company may not secure or maintain relationships with Craft Health, pharmacy partners, healthcare providers or other third parties; that the CraftMake™ system or related workflows may not perform as intended or meet regulatory, technical or commercial requirements; that the Company may not identify or retain suitable pharmacy partners for system placement; and that the anticipated recurring-revenue model may not be achieved or may not be commercially viable.

Additional risks include uncertainties relating to regulatory approvals, interpretations or changes in laws governing telehealth, pharmacy compounding, peptides, bulk drug substances, medical devices, data privacy and healthcare services; the possibility that regulatory authorities may not adopt or implement advisory committee recommendations; competition; intellectual property protection; product liability; cybersecurity and data protection risks; supply chain constraints; and the need for additional financing to fund development and commercialization activities.
Market and industry data referenced in this release are based on third-party sources believed to be reliable but have not been independently verified by the Company. Estimates regarding the number of compounding pharmacies in the United States are approximate and do not represent confirmed qualified partners or customers for the PERSONALIZ3D™ platform.

Readers are cautioned not to place undue reliance on forward-looking information. Except as required by applicable securities laws, PharmaTher undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. Additional risk factors are described in the Company’s continuous disclosure filings available on SEDAR+. This release does not constitute an offer to sell or a solicitation to buy securities.

TORONTO, ON — July 29, 2026 — PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) (“PharmaTher” or the “Company”), a specialty pharmaceutical company focused on personalized medicines, announced today a collaboration with Craft Health Pte. Ltd. (“Craft Health”) to evaluate Craft Health’s CraftMake™ GMP-ready pharmaceutical 3D printing platform for PharmaTher’s Personaliz3D Peptides™ partner ecosystem.
​
The collaboration will focus on developing novel peptide formulations and evaluating CraftMake™ as a reproducible platform for producing personalized peptide doses, combination formulations, controlled-release designs and differentiated dosage forms.
PharmaTher also intends to explore a broader commercial relationship with Craft Health that could support the deployment of CraftMake™ with qualified Section 503A compounding pharmacies and advance PharmaTher’s Personaliz3D Peptides™ initiative.

The collaboration follows PharmaTher’s recently announced launch of Personaliz3D Peptides™, an integrated personalized peptide initiative intended to connect physician oversight, telemedicine, qualified pharmacies, 3D printing, artificial intelligence and proprietary formulations.

“Personaliz3D Peptides™ is not intended to simply repackage traditional compounding. Our objective is to build a repeatable technology and formulation platform that may give qualified healthcare providers greater control over dose, combination, release profile and dosage format,” said Fabio Chianelli, Chief Executive Officer of PharmaTher. “Craft Health offers an integrated platform combining pharmaceutical 3D printer, software and formulations, including CraftMake™’s GMP-ready design and manufacturing standards, which we believe are needed to advance personalized peptide products from concept to practical deployment. Together, we aim to provide qualified pharmacies and healthcare partners a more efficient and high quality pathway to personalized peptide care.”

Personalized Peptide Care Needs Better Manufacturing
Patients and healthcare providers are increasingly seeking treatment options that can be tailored to individual dosing requirements and treatment goals.

However, much of today’s peptide care market continues to rely on fixed doses, limited dosage formats and fragmented relationships among patients, prescribers, pharmacies, formulation developers and technology providers.

PharmaTher believes pharmacies and healthcare providers should not have to independently build every element required to offer personalized peptide products.

Combining PharmaTher’s Peptide Strategy with Craft Health’s 3D Printing Technology
PharmaTher intends to contribute its personalized medicine strategy, pharmaceutical development experience, peptide product priorities, healthcare relationships, and planned Personaliz3D Peptides™ partner ecosystem.

Craft Health brings an integrated pharmaceutical 3D printing platform consisting of:

CRAFTMAKE™ — GMP-ready Pharmaceutical 3D Printer
CraftMake™ uses semi-solid paste extrusion at room temperature without heat or ultraviolet-light curing. This processing approach allows the parties to evaluate peptide formulations without introducing heating or UV-curing steps during printing.

CraftMake™ can produce different shapes, sizes and geometries and supports single-material, multi-material and pill-in-pill configurations that may be used for taste masking or sequential release.

Craft Health’s CraftMake™ Production Plus is designed for GMP manufacturing, incorporating an enclosed printing environment, dual printheads capable of printing two materials concurrently, and has reported dosing accuracy of approximately ±1% and repeatability greater than 99%.

CRAFTCONTROL™ — Workflow and Printing Software
CraftControl™ is designed to coordinate printing activities across the CraftMake™ platform. Its capabilities include no-code printing, audit trails, dashboard and analytics functions, coordination across multiple printers and optional in-process camera monitoring.

CRAFTBLENDS™ — Printable Formulation Technology
CraftBlends™ consists of proprietary 3D printable formulations developed for different release profiles, including immediate, delayed or enteric, sustained-release and orally disintegrating formulations.

“Craft Health was established to automate mass customization by integrating pharmaceutical 3D printing hardware, software and formulations,” said Dr. Wei Jiang Goh, Co-Founder and Chief Executive Officer of Craft Health. “We believe there is a strong strategic fit between our technology platform and PharmaTher’s vision for personalized peptides. This collaboration will allow the parties to systematically evaluate peptide formulations, dosage designs and release profiles while creating a potential pathway for qualified healthcare and pharmacy partners to adopt personalized pharmaceutical manufacturing.”

The Plan: From Peptide Development to Commercial Deployment
PharmaTher and Craft Health intend to evaluate BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax—six peptides recently recommended by the U.S. Food and Drug Administration’s Pharmacy Compounding Advisory Committee (“PCAC”) for inclusion on the Section 503A Bulks List.

The evaluation is expected to assess priority peptides and combinations across a range of release profiles and dosage formats. Potential activities may include developing single- and combination-peptide formulations, patient-specific precision-dosing configurations, multi-layer and multi-material products, immediate-, delayed- and sustained-release designs, and unique dosage formats such as oral thin films, gummies and other potential formats.

PharmaTher also intends to evaluate a broader commercial relationship with Craft Health to deploy CraftMake™ with qualified Section 503A compounding pharmacies and support PharmaTher’s Personaliz3D Peptides™ partner ecosystem.

By combining PharmaTher’s personalized peptide strategy and partner ecosystem with Craft Health’s established 3D printing hardware, software and formulation capabilities, the collaboration is expected to accelerate the development, validation and potential deployment of Personaliz3D Peptides™. Rather than building the underlying manufacturing technology from the ground up, PharmaTher can focus its resources on priority peptide formulations, differentiated dosage forms and adoption by qualified pharmacy and healthcare partners. PharmaTher believes this collaboration represents an important step toward transforming Personaliz3D Peptides™ from a strategic vision into a practical and potentially scalable commercial platform.

ABOUT CRAFT HEALTH PTE. LTD.
Craft Health is a Singapore-based pharmaceutical technology company pioneering 3D printing for customized medicine. Its proprietary platform — comprising the CraftMake™ 3D printer, CraftControl™ software, and CraftBlends™ formulation database — uses a gentle, heat- and UV-free semi-solid extrusion process that preserves the integrity of sensitive active ingredients while enabling precise control over dosage, release profile, shape, and combination of actives in a single dose. Founded by pharmacists and formulation scientists, Craft Health was built to solve real-world challenges in compounding and personalized dosing, and its GMP-ready platform is designed to help compounding pharmacies, hospitals, and pharmaceutical partners move from lab-scale concept to consistent, on-demand production. This capability makes Craft Health a natural partner for evaluating next-generation therapeutics such as peptides, where formulation stability and dosing precision are critical.

For more information, visit CraftHealth.me.

ABOUT PERSONALIZ3D PEPTIDES™
Personaliz3D Peptides™ is focused on developing and commercializing personalized peptide solutions using 3D printing, artificial intelligence and pharmaceutical development technologies. The division intends to create an integrated personalized peptide ecosystem connecting patients, physicians and qualified pharmacies. Personaliz3D Peptides™ plans to develop customized doses, combination formulations, alternative delivery formats, proprietary protocols, software, intellectual property and commercial partnerships. For more information, visit PersonalizedPeptidesRx.com.

ABOUT PHARMATHER HOLDINGS LTD.
PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) is a specialty pharmaceutical company focused on personalized medicines, specifically peptides and psychedelics. For more information, visit PharmaTher.com.

FOR MORE INFORMATION
Fabio Chianelli
Chairman and Chief Executive Officer
PharmaTher Holdings Ltd.
Tel: 1-888-846-3171
Email: info@pharmather.com
Website: PharmaTher.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

FORWARD-LOOKING STATEMENTS
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws, including statements regarding the collaboration between PharmaTher and Craft Health; the evaluation of CraftMake™ as the potential primary 3D-printing platform for Personaliz3D Peptides™; and the development, testing, validation, manufacture and commercialization of personalized peptide formulations and dosage forms.
Forward-looking statements include statements concerning the compatibility of peptides with semi-solid extrusion and Craft Health’s technology platform; the development of single-peptide and combination formulations; patient-specific dosing; multi-layer, multi-material and pill-in-pill products; immediate, delayed, sustained and other release profiles; and the potential development of tablets, capsules, chewables, gummies, beads, granules and other formats.
Forward-looking statements also include statements regarding technical and quality testing; dose accuracy; content uniformity; stability; reproducibility; equipment performance; software integration; printing recipes; operating procedures; intellectual property; regulatory compliance; GMP-related activities; and the potential transfer or deployment of CraftMake™ systems with qualified pharmacies and healthcare partners.
Additional forward-looking statements relate to potential collaborations with Section 503A compounding pharmacies, physicians, clinics, hospitals, researchers, pharmaceutical companies and technology providers; the establishment of a pharmacy and healthcare partner network; and potential equipment, formulation, software, consumable, licensing, training, service, royalty and product revenues.
Forward-looking statements are based on management’s current expectations, estimates, projections, assumptions and beliefs and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied.
These risks and uncertainties include the possibility that CraftMake™ may not be suitable for one or more peptides; that formulations may not achieve the required stability, accuracy, uniformity, release characteristics or reproducibility; that development or validation activities may be delayed, unsuccessful or more expensive than anticipated; and that the parties may not enter into additional commercial agreements.
Additional risks include regulatory changes; restrictions affecting peptide compounding; failure to obtain required approvals or establish compliant quality systems; inability to protect intellectual property; failure to establish pharmacy or healthcare partnerships; technology or equipment performance issues; competition; financing requirements; supply-chain constraints; and the other risks described in PharmaTher’s public disclosure documents available under its profile on SEDAR+.
Readers are cautioned not to place undue reliance on forward-looking statements. PharmaTher undertakes no obligation to update or revise any forward-looking statements except as required by applicable law.
This news release does not constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful.

New division will address the limitations of traditional peptide compounding through 3D printing and AI

PharmaTher plans to connect patients, physicians and qualified pharmacies through an integrated telemedicine platform

Positive PCAC recommendations represent an important potential step toward regulated access to compounded peptides in the United States

TORONTO, ON — July 27, 2026 — PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) (“PharmaTher” or the “Company”), a specialty pharmaceutical company focused on personalized medicines, announced today the launch of Personaliz3D Peptides™, a new division focused on developing and commercializing personalized peptide products and protocols using 3D printing and artificial intelligence technologies.

Patients and healthcare providers are increasingly seeking peptide therapies tailored to individual treatment goals. However, traditional peptide compounding is often limited to fixed doses, injectable or liquid formulations, and fragmented access through separate prescribers, pharmacies and technology providers, with additional variability in quality standards and limited access to verified GMP-compliant manufacturing controls.

PharmaTher established Personaliz3D Peptides™ to help address these limitations.

The division intends to create an integrated personalized peptide ecosystem that leverages 3D printing and artificial intelligence alongside physician oversight, telemedicine, qualified compounding pharmacies, proprietary formulations, and precise dosing to enable more advanced and individualized treatment design, including alternative delivery formats. Potential formats may include gummies, oral films, tablets, gels, chews, suppositories and patches.

The launch follows last week’s positive votes by the U.S. Food and Drug Administration’s Pharmacy Compounding Advisory Committee (“PCAC”), which recommended that BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax be included on the Section 503A Bulks List.

PharmaTher believes the PCAC recommendations represent an important potential step toward establishing a responsible regulatory framework for the development, compounding and clinical evaluation of personalized peptide medicines in the United States.

“Patients and healthcare providers should not have to rely on a one-size-fits-all approach when individual treatment needs can differ significantly,” said Fabio Chianelli, Chairman and Chief Executive Officer of PharmaTher. “Personaliz3D Peptides™ is being built to make personalized peptide care more precise, convenient, connected and manufactured under strict quality and GMP-aligned standards. By bringing together physician oversight, telemedicine, qualified pharmacies with the support of 3D printing and artificial intelligence, we intend to develop customized doses, proprietary protocols, combination formulations and alternative delivery formats within one integrated personalized peptides ecosystem.”

The Problem: Peptide Care Remains Fragmented

Interest in peptides continues to grow among patients, healthcare providers, pharmacies and researchers. Yet the current peptide care experience can be difficult to navigate.
Patients may encounter limited dosage options, inconvenient administration methods, concerns around peptide quality and consistency, and little ability to personalize a formulation to their individual requirements or access standardized GMP-manufactured finished product alternatives. Healthcare providers and pharmacies may also lack access to integrated technology, validated formulations and scalable systems for producing more customized peptide products.

PharmaTher believes personalized pharmaceutical manufacturing may provide a better path forward.

Rather than requiring every patient to receive the same product in the same dose and format, a 3D printing system may allow qualified providers to produce formulations based on specific dosing, combination and release-profile requirements, while also enabling quality assurance through GMP production standards and Certificates of Analysis.

Artificial intelligence may further support the development and optimization of formulations, protocols and patient-specific treatment pathways.

The Guide: PharmaTher’s Personalized Medicine Platform

PharmaTher intends to use its pharmaceutical development experience, 3D printing systems, and AI-assisted capabilities to help physicians and pharmacies deliver more personalized peptide solutions.

Personaliz3D Peptides™ is designed to bring these capabilities together with strategic 503A pharmacy, physician, healthcare and technology partnerships.

“Our role is to provide the tools, formulations, protocols and partnerships that may help qualified healthcare providers offer more individualized peptide solutions,” continued Mr. Chianelli.

“We intend to simplify a fragmented process and build a platform through which patients can be assessed by a physician, prescribed an appropriate personalized solution and connected with a qualified pharmacy capable of preparing the prescribed product.”

The Plan: Connect, Personalize and Deliver

PharmaTher intends to build the Personaliz3D Peptides™ ecosystem through a clear three-part strategy:

1. Connect

The Company plans to establish a focused personalized peptide telemedicine platform at PersonalizedPeptidesRx.com, which is currently under development.

The platform is intended to connect eligible patients with qualified healthcare providers who can assess individual needs, determine whether peptide therapy may be appropriate and provide ongoing medical oversight.
​
2. Personalize

PharmaTher plans to use 3D printing and AI-assisted technologies to develop proprietary peptide formulations, protocols and dosage formats that may be utilized by qualified peptide providers, including 503A compounding pharmacies, as well as physicians, clinics and other licensed healthcare practitioners involved in personalized peptide care.

Potential personalization capabilities may include:

• Patient-specific dosing;
• Precise micro-dosing;
• Combination peptide formulations;
• Immediate, delayed or sustained-release profiles; and
• Alternative formats such as tablets, oral films, gels, chews, gummies, suppositories and patches.

3. Deliver

The Company intends to establish relationships with qualified 503A compounding pharmacies, physicians, clinics, hospitals, researchers, technology providers and pharmaceutical companies.

These partners may support the compliant development, preparation and delivery of personalized peptide solutions while retaining responsibility for their respective professional, regulatory, manufacturing and patient care obligations.

The Desired Outcome: A Scalable Personalized Peptide Ecosystem

The objective is to create an integrated ecosystem through which:

• Patients may gain access to more convenient and individualized peptide options;
• Physicians may prescribe doses, combinations and delivery formats based on patient-specific needs;
• Pharmacies may access proprietary formulations, technologies, training and operating support; and
• Researchers and pharmaceutical companies may develop and evaluate new peptide products and protocols.

The division’s initial priorities are expected to include:

• Establishing the PersonalizedPeptidesRx.com telemedicine platform;
• Developing proprietary peptide formulations and protocols;
• Creating alternative and non-invasive dosage formats;
• Advancing precise dosing and combination product capabilities;
• Establishing collaborations with 503A compounding pharmacies and healthcare providers;
• Developing training, certification and onboarding programs;
• Integrating pharmacy, physician and patient data; and
• Pursuing intellectual property relating to production methods, formulations, protocols, software and personalized medicine technologies.

Commercialization Strategy

PharmaTher intends to pursue a partnership-driven commercialization model designed to support independent healthcare providers and pharmacies while building multiple potential revenue channels and intellectual-property opportunities across the platform.

The Personaliz3D Peptides™ commercialization model may generate revenue from:

• Personalized peptide solutions offered through the telemedicine platform;
• 3D printing systems, equipment placements and related services;
• Telemedicine and pharmacy platform participation arrangements;
• Licensing of proprietary formulations, protocols, software and AI-assisted tools;
• Consumables and pharmaceutical manufacturing materials;
• Formulation development and small-batch manufacturing services;
• Training, certification and onboarding programs; and
• Sales, royalties and milestone payments from proprietary or partnered products.

PharmaTher believes this model may allow independent pharmacies and healthcare providers to participate in a broader personalized peptide platform while maintaining responsibility for their own professional, regulatory and patient-care obligations.

The Company is currently establishing an integrated network of qualified pharmacy, healthcare, technology and supply partners designed to support product development, GMP-compliant manufacturing, data integration and the future delivery of personalized peptide solutions.

The PCAC recommendation is advisory and non-binding and does not constitute FDA approval or authorize compounding under Section 503A. Compounded drugs are not FDA-approved or evaluated by the FDA for safety, effectiveness or quality. Any related activities by PharmaTher or its partners will be subject to applicable laws and regulatory requirements.

About Personaliz3D Peptides™

Personaliz3D Peptides™ is focused on developing and commercializing personalized peptide solutions using 3D printing, artificial intelligence and pharmaceutical development technologies.

The division intends to create an integrated personalized peptide ecosystem connecting patients, physicians, and qualified pharmacies.

Personaliz3D Peptides™ plans to develop customized doses, combination formulations, alternative delivery formats, proprietary protocols, software, intellectual property and commercial partnerships.

For more information, visit PersonalizedPeptidesRx.com.

About PharmaTher Holdings Ltd.

PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) is a specialty pharmaceutical company focused on personalized medicines, specifically peptides and psychedelics. For more information, visit PharmaTher.com.

For more information about PharmaTher, please contact:

Fabio Chianelli
Chief Executive Officer
PharmaTher Holdings Ltd.
Tel: 1-888-846-3171
Email: info@pharmather.com
Website: PharmaTher.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Cautionary and Forward-Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws, including, but not limited to, statements regarding the establishment, development, strategy, objectives and commercialization of the Personaliz3D Peptides™ division; the development and operation of PersonalizedPeptidesRx.com; the creation of an integrated personalized-peptide ecosystem; the potential implications of the FDA Pharmacy Compounding Advisory Committee recommendations concerning BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax; future FDA decisions, rulemaking or regulatory actions; and the potential inclusion of peptide-related bulk drug substances on the Section 503A Bulks List.

Forward-looking statements also include statements concerning the development, manufacture, compounding, regulatory status, adoption and commercialization of personalized peptide products; the development, validation, scalability, deployment and commercial use of 3D-printing technologies; the potential functionality of robotic 3D printing, artificial intelligence and telemedicine; patient-specific dosing, micro-dosing, combination products, release profiles and alternative pharmaceutical formats; and the development of proprietary formulations, printing recipes, protocols, software, manufacturing processes, intellectual property and formulation data. Additional forward-looking statements relate to potential collaborations with pharmacies, physicians, telehealth providers, healthcare facilities, research institutions, pharmaceutical companies, technology providers and supply partners; the development of a pharmacy and healthcare partner network; the integration of patient, physician and pharmacy data; potential equipment, licensing, service, software, consumable, telemedicine, royalty and product revenues; and the Company’s ability to finance, execute and realize value from its personalized-medicine strategy. Forward-looking statements are based on management’s current expectations, estimates, projections, assumptions and beliefs and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements.

These risks and uncertainties include, among others, the possibility that the FDA may not accept or implement the PCAC recommendations; that regulatory requirements may change; that BPC-157, KPV, TB-500, MOTS-c, Epitalon, Semax or other peptide-related bulk drug substances may not become eligible for lawful compounding or may be subject to additional restrictions; and that PersonalizedPeptidesRx.com may not be successfully developed, launched or adopted. Additional risks include the possibility that 3D printing technologies may not be completed, validated and GMP-compliant, commercialized or adopted as anticipated; that Personaliz3D Peptides™ may not be successfully established or achieve its intended objectives; that the Company may be unable to develop, protect or commercialize proprietary formulations, protocols, printing recipes or personalized peptide products; and that the Company may be unable to establish commercial partnerships or develop commercially viable products or services.

Readers are cautioned not to place undue reliance on forward-looking information, which speaks only as of the date of this news release. Except as required by applicable law, PharmaTher undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. Additional risk factors are described in the Company’s continuous disclosure filings available under the Company’s profile on SEDAR+. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.

This news release does not constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful.

Collaboration combines more than 9,000 KetaMist® patient treatments with PharmaTher’s prior FDA-approved ketamine experience
​
Pursuing an efficient FDA development pathway toward approval for treatment-resistant depression and other potential indications, leveraging KetaMist’s real-world treatment foundation

KetaMist represents a differentiated, patient-controlled ketamine platform with the potential to build a multi-indication ketamine franchise

TORONTO, ON — July 21, 2026 — PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) (“PharmaTher” or the “Company”), a specialty pharmaceutical company focused on personalized medicines for peptides and psychedelics, today announced a collaboration with Curtis W. Cassidy, M.D., the inventor and developer of KetaMist® (ketamist.com), a needle-free ketamine treatment platform, to pursue U.S. Food and Drug Administration (“FDA”) approval for treatment-resistant depression (TRD) and other neuropsychiatric and medical conditions where ketamine has demonstrated therapeutic benefit.

KetaMist is a proprietary, patient-controlled and needle-free ketamine treatment platform developed by Dr. Cassidy for patients with treatment-resistant depression and other conditions. According to Dr. Cassidy, KetaMist has been used in more than 9,000 patient treatments, creating a meaningful body of real-world clinical experience that PharmaTher believes may support an efficient and potentially expedited FDA development strategy.

Targeting the Large and Growing TRD Market While Building a Ketamine Franchise
Treatment-resistant depression represents a significant unmet medical need, affecting millions of patients in the United States who do not respond adequately to standard antidepressant therapies. The current FDA-approved ketamine-based therapy for TRD, Spravato® (esketamine nasal spray), has demonstrated strong commercial traction, generating approximately $1.7 billion in worldwide sales in 2025, with trailing twelve-month sales through June 30, 2026 of approximately $2.0 billion.1 Analysts have reportedly projected that Spravato could generate approximately $3 billion in annual sales by 2027 and up to $5 billion in peak annual sales, highlighting the significant commercial opportunity for differentiated ketamine-based treatments.2

PharmaTher believes KetaMist has the potential to compete in this large and growing market by offering a differentiated treatment approach that may address certain limitations associated with existing therapies.

KetaMist is designed as a patient-controlled and needle-free delivery system, which may offer several potential advantages, subject to FDA approval:

• Personalized dosing and administration, allowing physicians to tailor treatment to individual patient response;
• Simplified delivery method, potentially improving patient comfort and accessibility;
• Potential for broader clinical adoption, depending on regulatory requirements and labeling; and
• Use of racemic ketamine, which may provide a differentiated pharmacological profile compared to esketamine.

Beyond TRD, PharmaTher views KetaMist as a franchise platform with the potential to be developed across multiple indications where ketamine has already demonstrated clinical utility, including but not limited to depression, anxiety disorders, post-traumatic stress disorder (PTSD), chronic pain, and other neuropsychiatric and neurological conditions. While many of these uses are currently off-label, the Company believes KetaMist’s flexible and personalized delivery approach may support expansion into additional therapeutic areas over time, subject to regulatory approval.

A Potentially Expedited Path Toward FDA Approval
PharmaTher and Dr. Cassidy plan to work with the FDA to find an efficient path to approval for KetaMist.

Because ketamine is already an FDA-approved drug, the Company may be able to build on existing knowledge. KetaMist has already been used in more than 9,000 patient treatments, providing real-world experience on how the therapy is administered, how patients respond, and overall safety. PharmaTher will prepare regulatory documents to help guide discussions with the FDA toward a potentially expedited approval pathway.

Leveraging PharmaTher’s FDA-Approved Ketamine Foundation
PharmaTher previously obtained FDA approval for Ketamine Hydrochloride Injection USP under ANDA #217858, demonstrating the Company’s ability to complete the regulatory, manufacturing, analytical and quality requirements necessary to secure an FDA ketamine approval.

Although PharmaTher completed its sale of its ANDA in December 2025, the Company retained its rights to pursue non-generic ketamine opportunities, including new formulations, delivery technologies and therapeutic indications. PharmaTher also retained significant regulatory and product-development experience generated through the successful ANDA program.

As part of the KetaMist collaboration, PharmaTher intends to apply its ketamine regulatory, analytical and chemistry, manufacturing and controls experience to the KetaMist development program and seek FDA feedback on the most efficient pathway toward approval.

Positioned at the Intersection of Ketamine, Personalized Medicine and Regulatory Momentum
The collaboration follows PharmaTher’s recently announced strategy to advance personalized medicines for peptides and psychedelics through differentiated products, enabling technologies and regulatory pathways.

KetaMist is aligned with that strategy because its patient-controlled delivery approach is intended to allow treatment to be adjusted to individual patient response rather than relying solely on a standardized administration model.

Importantly, PharmaTher believes KetaMist’s design supports its development as a multi-indication ketamine franchise, leveraging the well-established pharmacology of ketamine and its broad therapeutic potential across numerous conditions.
The program also arrives during a period of increased U.S. regulatory attention toward ketamine and innovative mental-health treatments.

PharmaTher believes that recent regulatory precedents demonstrate increasing openness to development strategies that incorporate real-world data and leverage existing clinical experience to support more efficient pathways to approval. While each program is evaluated independently by the FDA, these precedents may provide a framework for engaging with regulators on potential expedited development approaches.

“KetaMist fits our strategy perfectly—a doctor-developed ketamine treatment with over 9,000 patient uses and a path to FDA approval. While we are initially focused on treatment-resistant depression, we believe KetaMist represents a broader franchise opportunity across multiple indications where ketamine has already shown clinical benefit. By combining this real-world experience with our prior FDA-approved ketamine work, we believe we can move faster and more efficiently than traditional drug development and unlock meaningful value across several large markets,” said Fabio Chianelli, Chief Executive Officer of PharmaTher.

Dr. Curtis W. Cassidy commented: “I developed KetaMist to give physicians and patients a more personalized and accessible approach to ketamine treatment. After more than 9,000 patient treatments, we have gained substantial practical experience regarding how patients respond and how treatment may be individualized across a range of conditions. PharmaTher shares that focus on personalized medicine and has the pharmaceutical-development and FDA experience needed to take the next important step toward broader access and potential regulatory approval.”

Near-Term Development Priorities
The collaboration activities will include preparing an FDA meeting package to obtain guidance for a potentially accelerated path toward FDA approval.

Near-term milestones are expected to include regulatory engagement with the FDA, definition of the clinical and data requirements for a potential NDA submission, and evaluation of how existing real-world data may support the development program.

The collaboration agreement provides PharmaTher with a one-year evaluation period to assess KetaMist for potential development and commercial testing. During this period, the parties may negotiate and enter into one or more additional agreements (each a “Possible Transaction”) relating to the further development and commercialization of KetaMist, subject to mutually acceptable terms.

KetaMist is not currently approved by the FDA, and its existing clinical use is considered off-label. There can be no assurance that the FDA will accept the proposed regulatory pathway, that the existing treatment information will be suitable for regulatory use, or that KetaMist will receive FDA approval.

About KetaMist®
KetaMist® is a proprietary, patient-controlled and needle-free ketamine treatment platform developed to provide a more personalized approach for patients with treatment-resistant depression and other neuropsychiatric and medical conditions. The system is designed to allow physicians to tailor dosing and administration based on individual patient response, offering flexibility compared to traditional ketamine delivery methods.

KetaMist has been used in more than 9,000 patient treatments, generating meaningful real-world clinical experience related to dosing, administration, safety observations and patient outcomes. For more information, visit Ketamist.com

About PharmaTher
PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) is a specialty pharmaceutical company focused on developing, acquiring and commercializing personalized medicines and enabling technologies, with an emphasis on peptides and psychedelics. For more information, visit PharmaTher.com.

For more information, please contact:
Fabio Chianelli
Chief Executive Officer
PharmaTher Holdings Ltd.
Tel: 1-888-846-3171
Email: info@pharmather.com
Website: PharmaTher.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Cautionary and Forward-Looking Statements
This news release contains “forward-looking information” and “forward-looking statements” within the meaning of applicable Canadian securities laws, collectively referred to as “forward-looking information.” Forward-looking information is often identified by words such as “believe,” “expect,” “plan,” “intend,” “may,” “could,” “would,” “should,” “anticipate,” “potential,” “proposed,” “target,” “seek,” “estimate,” “forecast,” “position,” “develop,” “advance,” “expedite,” “accelerate,” “commercialize” and similar expressions, or statements that certain events or conditions “will,” “may” or “could” occur.
This press release contains forward-looking statements regarding, among other matters, the collaboration with Dr. Cassidy, the evaluation and development of KetaMist, the proposed regulatory pathway, the potential use of real-world data, future FDA interactions, required studies, intellectual-property, development, and commercial opportunities, possible transaction, and the potential submission or approval of an NDA. Forward-looking statements are based on management’s current expectations and assumptions and are subject to regulatory, clinical, manufacturing, intellectual-property, financing, competitive and other risks and uncertainties. There can be no assurance that the FDA will agree with the proposed development plan, that available data will be suitable for regulatory purposes, that required studies will be successful, that sufficient financing or partnerships will be obtained, or that KetaMist will receive regulatory approval or achieve commercialization.
Forward-looking information is based on management’s current expectations, estimates, forecasts, beliefs and assumptions as of the date of this news release. Material assumptions include, without limitation, that: the collaboration will remain in effect and the parties will perform their respective obligations; information regarding prior KetaMist treatments is accurate, complete, accessible and capable of being reviewed or organized for regulatory purposes; the Company will be able to engage with the FDA within anticipated timelines; the FDA will provide guidance that permits a feasible development pathway; any required studies can be designed, funded and successfully completed; suitable manufacturing, analytical, clinical and supply-chain capabilities can be obtained; the Company will have access to sufficient capital, personnel and third-party expertise; intellectual-property and commercial rights can be maintained or secured; the Company will enter into one or more possible transactions; applicable laws and regulatory policies will not change in a materially adverse manner; and market-size information, commercial estimates and third-party analyst forecasts referenced in this news release are reasonably accurate. These assumptions may prove to be incorrect. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that could cause actual results, events or achievements to differ materially from those expressed or implied. Such risks include, without limitation: the possibility that the FDA may not agree with the Company’s proposed development or regulatory strategy; that KetaMist may not qualify for an expedited or accelerated pathway; that the FDA may require substantial additional non-clinical, clinical, manufacturing, human-factors or other studies; that real-world data or information from prior patient treatments may be incomplete, inconsistent, retrospective, unverifiable or unsuitable for regulatory reliance; that existing treatment experience may not demonstrate safety or efficacy to the FDA’s satisfaction; that studies may be delayed, unsuccessful or more costly than expected; and that KetaMist may never receive regulatory approval.
Readers are cautioned not to place undue reliance on forward-looking information, which speaks only as of the date of this news release. Except as required by applicable law, PharmaTher undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. Additional risk factors are described in the Company’s continuous disclosure filings available under the Company’s profile on SEDAR+. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.

This news release does not constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful.

Footnotes

1. Johnson & Johnson, “Johnson & Johnson Reports Q4 and Full-Year 2025 Results,” January 21, 2026, reporting worldwide Spravato sales of $1.696 billion for the year ended December 31, 2025; and Johnson & Johnson, “Johnson & Johnson Reports Q2 2026 Results, Raises 2026 Outlook,” July 15, 2026, reporting worldwide Spravato sales of $1.052 billion for the six months ended June 30, 2026, compared with $734 million for the corresponding six-month period in 2025. Trailing twelve-month sales through June 30, 2026 were calculated as follows: $1.696 billion less $734 million, plus $1.052 billion, equalling approximately $2.014 billion. Figures may not add precisely due to rounding.
2. “Johnson & Johnson’s Spravato Sales Growth Signals Upside for Psychedelic Drug Opportunity: Jefferies,” April 14, 2026. The report stated that Jefferies projected Spravato annual sales of approximately $3 billion by 2027, $3.5 billion by 2028 and potential peak annual sales of up to $5 billion. These projections are analyst estimates and are not guarantees of future performance.

TORONTO, ON — July 15, 2026 — PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) (“PharmaTher” or the “Company”), a specialty pharmaceutical company focused on personalized medicines, today provided a corporate update outlining its strategic focus on personalized medicines, specifically peptides and psychedelics.

PharmaTher believes peptides and psychedelics are gaining strong momentum and plans to capitalize on this opportunity using its MEDBOTX™ 3D-printing platform and AI-driven formulation tools. The Company’s main focus is personalized medicines, aiming to develop treatments tailored to individual patient needs.

“Medicine is shifting toward treatments tailored to each patient,” said Fabio Chianelli, Chairman and Chief Executive Officer of PharmaTher. “We see peptides and psychedelics as key growth areas and aim to position PharmaTher at the forefront of personalized healthcare using AI and advanced manufacturing.”

One Platform, Two Emerging Therapeutic Categories

PharmaTher’s personalized-medicine strategy will initially focus on two therapeutic categories:

Personalized Peptides

Peptides are gaining strong interest, but traditional manufacturing often cannot deliver personalized doses or flexible formats. PharmaTher aims to solve this using its MEDBOTX™ 3D-printing platform and AI to create customized peptide products, including tailored doses, combination therapies, controlled-release options, and multiple formats such as tablets, films, gels, and patches.

The FDA’s Pharmacy Compounding Advisory Committee is scheduled to meet on July 23 and 24, 2026, to consider several peptide-related bulk drug substances for potential inclusion on the Section 503A Bulks List. The substances include BPC-157, KPV, TB-500, MOTS-C, emideltide, Semax and Epitalon. The meeting reflects increased formal regulatory attention to peptides, although there can be no assurance that the advisory committee will recommend, or the FDA will approve, the inclusion of any substance on the 503A Bulks List.

PharmaTher believes that greater regulatory clarity could create opportunities for compliant pharmaceutical development, compounding, patient-specific formulation and advanced manufacturing technologies.

Personalized Psychedelics

PharmaTher also plans to apply its personalized-medicine platform to psychedelics, where precise dosing and tailored delivery are important, and believes its 3D printing and AI capabilities can offer a way to develop these therapies.

The regulatory environment for psychedelic drug development is improving. In July 2026, the FDA issued its first guidance on clinical studies for psychedelic drugs, helping define how treatments for mental health and substance-use disorders can be developed. The FDA has also issued priority vouchers to companies and has publicly supported the advancement of psychedelic therapies. In addition, the U.S. Department of Health and Human Services and Department of Veterans Affairs announced a five-year collaboration to support research and the potential future use of FDA-approved psychedelic treatments for veterans.

These developments do not constitute regulatory approval of any psychedelic product. However, PharmaTher believes they demonstrate growing institutional support for the responsible investigation and development of psychedelic medicines.

Powered by MEDBOTX™ and Artificial Intelligence

MEDBOTX™ is PharmaTher’s robotic 3D-printing platform, developed for personalized medicines. The platform is intended to provide key product characteristics, potentially including:

• Immediate, sustained or delayed release;
• Multiple release phases within one product;
• Patient-specific dosing; and
• Alternative pharmaceutical delivery formats.

The Company intends to continue advancing MEDBOTX™ as a core component of its personalized-medicine strategy, with a focus on integrating formulation development, manufacturing capabilities and scalable applications to support future commercialization efforts.

PharmaTher’s Commercialization Strategy and Priorities

​PharmaTher intends to pursue a capital-efficient business model that may include:

• Developing proprietary peptide and psychedelic formulations;
  
• Entering partnerships with 503A compounding pharmacies, hospitals, and research institutions;
  
• Collaborating with pharmaceutical and biotechnology companies;
  
• Supplying MEDBOTX™ systems, formulation inputs and related consumables; and
  
• Participating in the commercialization of selected personalized-medicine products.

“Our vision is to position PharmaTher at the forefront of personalized medicine, where innovation in peptides, psychedelics, and advanced manufacturing can meaningfully improve patient outcomes,” concluded Mr. Chianelli.

About PharmaTher Holdings Ltd.

PharmaTher Holdings Ltd. (CSE: PHRM; OTCQB: PHRRF) is a specialty pharmaceutical company focused on personalized medicines, specifically peptides and psychedelics. For more information, visit PharmaTher.com.

For more information, please contact:
Fabio Chianelli
Chief Executive Officer
PharmaTher Holdings Ltd.
Tel: 1-888-846-3171
Email: info@pharmather.com
 
Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

Forward-looking statements are often identified by words such as “believe,” “expect,” “plan,” “intend,” “may,” “could,” “would,” “should,” “anticipate,” “potential,” “opportunity,” “designed,” “developing,” “target,” “focus,” “strategy,” “commercialization,” “milestone,” and similar expressions. These statements are based on management’s current expectations, assumptions and beliefs as of the date of this news release and are subject to known and unknown risks, uncertainties and other factors that could cause actual results, events or achievements to differ materially from those expressed or implied by such forward-looking statements.
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. Forward-looking statements include, but are not limited to, statements concerning PharmaTher’s strategic focus on personalized medicines, including peptides and psychedelics; the development, completion, validation, commercialization and potential functionality of MEDBOTX™; AI-assisted formulation development; proprietary formulations, printing recipes, manufacturing processes, software and intellectual property; pharmaceutical, pharmacy, healthcare and technology partnerships; product-development and commercialization opportunities; potential revenue models; regulatory developments involving peptides and psychedelics; and the potential value or monetization of the Company’s assets and investment holdings.
Forward-looking statements are based on management’s current expectations, assumptions and beliefs and are subject to significant risks, uncertainties and other factors that could cause actual results to differ materially. There can be no assurance that MEDBOTX™ will be successfully completed, validated, commercialized or adopted; that any proposed peptide or psychedelic product will be developed, approved, compounded or commercialized; that any regulatory authority will permit the proposed use of a substance or product; that any partnership or licensing transaction will be completed; or that the Company will generate revenue from its personalized-medicine strategy.
Peptide and psychedelic products described in this release may be investigational, unapproved or subject to restrictions under applicable laws. Regulatory developments referenced in this release, including FDA advisory committee discussions, guidance documents or government initiatives, do not constitute approval or authorization of any product or substance. Readers are cautioned not to place undue reliance on forward-looking statements. Except as required by applicable law, PharmaTher undertakes no obligation to update or revise such statements.
Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this news release. Except as required by applicable law, PharmaTher undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Additional risk factors are described in the Company’s continuous disclosure filings available under the Company’s profile on SEDAR+.
This news release does not constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful.

MEDBOTX™ represents the evolution into a broader point-of-care manufacturing platform designed for personalized medicines, peptides and advanced dose formats

Potential U.S. peptide reclassification and possible inclusion of select peptides on the Section 503A Bulks List could create a timely opportunity for MEDBOTX™ in compounding pharmacies, hospitals and personalized medicine settings
​
TORONTO, ON — May 27, 2026 — PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) (“PharmaTher” or the “Company”), a pharmatech company focused on enabling personalized medicine through robotic 3D printing, today announced that it is strategically evolving its platform focus from PatchPrint™ 3D printer to MEDBOTX™, the Company’s robotic 3D printing platform designed for personalized medicines, peptides and advanced pharmaceutical dose formats.

Figure 1. Prototype of MEDBOTX™ robotic 3D printing platform

​PharmaTher believes MEDBOTX™ represents the next stage of the Company’s growth and the evolution of its work in pharmaceutical R&D, microneedle patches, and 3D printing. By expanding beyond a single-dose format such as microneedle patches, MEDBOTX™ gives PharmaTher a broader and more scalable platform for personalized, patient-specific and small-batch pharmaceutical manufacturing. The Company expects MEDBOTX™ to become the central technology platform for its product development and sales, partnerships, and strategy in personalized medicines.

“MEDBOTX™ represents the next stage of PharmaTher’s work in pharmaceutical drug development and manufacturing,” said Fabio Chianelli, Chief Executive Officer of PharmaTher. “We believe our MEDBOTX™ platform provides a focused path to participate in the growing demand for personalized medicines, particularly peptides, where flexible, small-batch and point-of-care manufacturing may become increasingly important as the U.S. evaluates potential regulatory pathways for certain peptide compounds and specialty pharmaceuticals.”

MEDBOTX™ is designed as a point-of-care and small-batch manufacturing platform that may support personalized dose forms, including polypills, tablets, oral films, gels, suppositories, chews, patches, osmotic-pump formats, and other advanced drug delivery formats. PharmaTher’s initial commercial focus is expected to include personalized medicines, regulated peptide opportunities, compounded pharmaceuticals, and partner-facing formulation and development services.

Figure 2. Potential dose formats from MEDBOTX™

MEDBOTX™ for Personalized Medicines
PharmaTher believes healthcare is moving toward greater personalization, including patient-specific dosing, alternative delivery formats, combination therapies, improved adherence and localized manufacturing. These trends are particularly relevant in settings where conventional mass manufacturing may not address the needs of specific patients, prescribers or clinical workflows.

MEDBOTX™ is designed to support this shift by enabling programmable, flexible and potentially scalable production of personalized medicines and advanced dose formats, which could be relevant for:

1. Hospitals and compounding pharmacies, including 503A pharmacies, seeking point-of-care capabilities to support individualized, prescription-based medicines;
2. PharmaTher’s internal product pipeline, including custom peptides, psychedelics, and microneedle patch development programs; and
3. Specialty pharmaceutical and biotech partners seeking formulation development and small-batch production for clinical studies and commercialization.

 
Peptides: A Timely Opportunity for MEDBOTX™
PharmaTher believes peptides represent an attractive near-term opportunity for MEDBOTX™. Peptides are an important and growing class of therapeutic compounds, but many can present formulation, stability, delivery and manufacturing challenges. These challenges may create a need for flexible manufacturing platforms capable of supporting customized dose forms, small-batch production and patient-specific formulations.

The U.S. regulatory activity involving therapeutic peptides could become an important external catalyst for MEDBOTX™. The U.S. Food and Drug Administration’s Pharmacy Compounding Advisory Committee is scheduled to meet on July 23–24, 2026, to discuss certain bulk drug substances being considered for possible inclusion on the Section 503A Bulks List, including BPC-157-related, KPV-related, TB-500-related and MOTs-C-related bulk drug substances.

If certain peptides gain a broader lawful pathway for compounding under appropriate medical supervision, PharmaTher believes MEDBOTX™ could become increasingly relevant as a platform for personalized peptide formulation development, small-batch production, and point-of-care manufacturing workflows in compound pharmacies and hospitals.

MEDBOTX™ Commercial Strategy
PharmaTher intends to focus its MEDBOTX™ commercialization strategy on platform opportunities that may include:

• System placements with compounding pharmacies, hospitals, clinics, research institutions and qualified partners;
• Consumables and formulation inputs that may support recurring revenue opportunities;
• Internal product development, including peptide and psychedelic formulations and microneedle patch programs;
• CDMO-style services for partners seeking formulation development and small-batch development; and
• Strategic collaborations involving bioprinting and bio-integrated applications, including hydrogel-based implants, tissue scaffolds, and smart wearables.

The Company expects its near-term MEDBOTX™ priorities to include advancing toward commercial launch, identifying commercial partnerships for regulated peptides and compounded pharmaceuticals, and positioning MEDBOTX™ as PharmaTher’s primary platform for personalized medicine manufacturing.

MEDBOTX™ Commercialization Milestones
The Company’s expected MEDBOTX™ commercialization milestones include:

Summer 2026: Completion of the MEDBOTX™ system for internal R&D and commercial demonstrations.

Fall 2026: Commencement of commercialization activities, including engagement with potential commercial partners, compounding pharmacy partners, hospitals, clinics, research institutions and pharmaceutical development collaborators.

Ongoing: Development of proprietary “printing recipes” for selected peptides and compounds, supported by GMP-aligned workflow software, AI-assisted formulation development, related process know-how, and new intellectual property filings to strengthen the Company’s personalized medicine and advanced manufacturing platform.

PharmaTher is currently collaborating with a bioprinting manufacturer to finalize customizations and scale up manufacturing of MEDBOTX™.

PharmaTher’s focus is clear: advance the MEDBOTX™ platform, engage commercial partners, develop proprietary formulation and manufacturing know-how, and build long-term value in the growing market for personalized medicines.

About MEDBOTX™
MEDBOTX™ is PharmaTher’s robotic 3D printing platform being developed for personalized medicines. MEDBOTX™ is designed to support point-of-care and small-batch manufacturing, including potential applications in compounding pharmacies, hospitals, clinics, research institutions, pharmaceutical partners, and PharmaTher’s development programs.
​
About PharmaTher Holdings Ltd.
PharmaTher Holdings Ltd. (CSE: PHRM; OTCQB: PHRRF) is a specialty pharmaceutical and technology company focused on developing, acquiring and commercializing pharmaceutical products and enabling technologies. The Company is advancing MEDBOTX™, a robotic 3D printing platform designed for personalized medicine, peptides and advanced dose formats, while continuing to evaluate strategic opportunities for its ketamine portfolio, PharmaPatch™ psychedelics research, and interest in Sairiyo Therapeutics Inc. For more information, visit PharmaTher.com.
For more information about PharmaTher, please contact:
 
Fabio Chianelli
Chief Executive Officer
PharmaTher Holdings Ltd.
Tel: 1-888-846-3171
Email: info@pharmather.com
Website: www.pharmather.com
 
Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking StatementsThis news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws, including, but not limited to, statements regarding the Company’s business strategy; the strategic evolution from PatchPrint™ to MEDBOTX™; the development, design, functionality, customization, validation, scalability, commercialization, deployment, adoption and potential use of MEDBOTX™; the Company’s collaboration with a bioprinting manufacturer to scale manufacturing of MEDBOTX™ systems; the expected completion of the MEDBOTX™ system for internal R&D and commercial demonstrations in Summer 2026; the expected commencement of commercialization activities in Fall 2026; the Company’s ability to engage commercial partners, compounding pharmacy partners, hospitals, clinics, research institutions and pharmaceutical development collaborators; and the potential use of MEDBOTX™ in personalized medicine, peptide formulation, compounded pharmaceuticals, point-of-care manufacturing, small-batch production, advanced dose formats, bioprinting, bio-integrated medical devices, tissue scaffolds, smart wearables and other healthcare applications.
Forward-looking statements also include statements regarding the development of proprietary “printing recipes” for selected peptides and compounds; formulation parameters; GMP-aligned workflow software; AI-assisted formulation development; related process know-how; new intellectual property filings; the Company’s internal R&D programs; potential system placements; consumables and formulation inputs; formulation R&D and CDMO-style services; licensing and co-development partnerships; and the potential for MEDBOTX™ to become PharmaTher’s central technology platform for product development, commercial partnerships and strategy in personalized medicines.
This news release also contains forward-looking statements regarding the potential U.S. regulatory reclassification of certain peptides; the possible inclusion of certain bulk drug substances on the Section 503A Bulks List; the timing, outcome, scope or impact of any FDA advisory committee meeting, public comment process, policy change or regulatory decision; and the potential relevance of BPC-157-related, KPV-related, TB-500-related, MOTs-C-related or other peptide compounds to the Company’s platform, product development, formulation, manufacturing or commercial strategy. There can be no assurance that any peptide will be included on the Section 503A Bulks List, that any regulatory change will occur, that any such change will create a lawful or commercially viable pathway for the Company, or that MEDBOTX™ will be used in connection with any specific peptide, compounded medicine or pharmaceutical product.
Forward-looking statements are often identified by words such as “believe,” “expect,” “expects,” “plan,” “plans,” “intend,” “may,” “could,” “would,” “should,” “anticipate,” “potential,” “opportunity,” “designed,” “developing,” “target,” “focus,” “strategy,” “commercialization,” “milestone,” and similar expressions. These statements are based on management’s current expectations, assumptions and beliefs as of the date of this news release and are subject to known and unknown risks, uncertainties and other factors that could cause actual results, events or achievements to differ materially from those expressed or implied by such forward-looking statements.
These risks and uncertainties include, among others, risks related to research and development; prototype design and completion; technology customization, manufacturing, scale-up, validation and performance; software development, GMP-aligned workflow integration and AI-assisted formulation development; formulation feasibility; intellectual property protection; the development and reproducibility of “printing recipes”; regulatory requirements applicable to medical, pharmaceutical, compounding, manufacturing, software, quality system and point-of-care production activities; the availability and cost of financing; the ability to attract and retain commercial partners; market acceptance; competition; changes in applicable laws, regulations, guidance or policy; the outcome of FDA or other regulatory reviews; supply chain constraints; reliance on third-party manufacturers, collaborators and service providers; and general economic, industry and capital market conditions.
There can be no assurance that MEDBOTX™ will be successfully developed, completed, validated, manufactured, commercialized, deployed or adopted; that the Company will meet its expected development or commercialization timelines; that any commercial partnerships, system placements, licensing arrangements, CDMO-style services, consumables revenue, formulation programs, intellectual property filings or other business opportunities will be completed or generate revenue; that any peptide-related regulatory development will occur or benefit the Company; or that any product, formulation, software, manufacturing process or technology described herein will receive regulatory approval, comply with applicable regulatory requirements or achieve commercial success. The product candidates, technologies, software, formulations, manufacturing processes and applications described in this news release are investigational, developmental or conceptual in nature and have not been approved by the U.S. Food and Drug Administration, Health Canada or any other regulatory authority. Safety, efficacy, quality, manufacturing suitability, regulatory compliance and commercial feasibility have not been established.
Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this news release. Except as required by applicable law, PharmaTher undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Additional risk factors are described in the Company’s continuous disclosure filings available under the Company’s profile on SEDAR+.
This news release does not constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful.